Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
AKORN (AKRX)
Last akorn earnings: 10/31 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.akorn.com
Company Research
Source: GlobeNewswire
LAKE FOREST, Ill., April 18, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Among other private label possibilities, we have a supply agreement in place for Fluticare® through Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV).” Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older. Fluticare® is a registered trademark of Innovus Pharmaceuticals, Inc. About AkornAkorn, Inc. is
Show less
Read more
Impact Snapshot
Event Time:
AKRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRX alerts
High impacting AKORN news events
Weekly update
A roundup of the hottest topics